Nephrology
-
Randomized Controlled Trial Multicenter Study
Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis.
While darbepoetin alfa (DA) can be administered once monthly (QM) to maintain haemoglobin (Hb) concentrations in anaemic patients with chronic kidney disease not on dialysis (CKD-ND), the QM use of DA for anaemia correction has not been previously investigated. ⋯ In subjects with CKD-ND, QM dosing was non-inferior to Q2W dosing for anaemia correction and had a similar safety profile.
-
Very little data exist regarding community-acquired acute renal injury (CA-AKI). We have identified and characterized a patient cohort with CA-AKI, and documented its impact on renal function and patient mortality. ⋯ CA-AKI carries significant implications in terms of both development of progressive renal disease and high long-term patient mortality.